Trial intelligence / Profile preview

Randomized phase III dasatinib dose-schedule study in chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib resistance or intolerance

2005-001294-99Phase 3Completed

Sponsor

Bristol Myers Squibb

Start

Jun 2005

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1